| Item number | Description |
|---|---|
| PSCC100 | PulseSelect PFA catheter |
| PSG100 | PulseSelect PFA generator |
PF ablation systems
PulseSelect™ pulsed field ablation system
<p>The PulseSelect™ pulsed field ablation (PFA) system enables both mapping and precise lesion delivery using biphasic waveform optimization.</p>
PulseSelect™ PFA system design and safety features
Proven safety
Engineered with safety features from over 15 years of PFA research and supported by one of the safest IDE AF ablation trials to date and several independent studies1–17
Consistent efficiency
Rapid, effective pulmonary vein isolation (PVI)1 through predictable energy delivery and stable catheter control
Simplified adaptability
A plug-and-play PFA system compatible with existing workflows3 with real-time contact feedback seamlessly integrated into the PulseSelect™ generator display
PFA designed for simplified adaptability
A plug-and-play PFA system with an integrated proximity indicator to complement existing contact assessment techniques.
- Nine active electrodes support real-time contact feedback, EGM sensing, pacing, and catheter visualization
- Visualization on existing mapping systems
- Compatible with intracardiac echocardiography (ICE) and fluoroscopy only workflows.
PulseSelect™ generator
- Automatic overcurrent detection for safe energy delivery
- R-wave gating for synchronization of energy delivery
- Test pulse for proximity detection to phrenic nerve
PulseSelect™ pulsed field ablation (PFA) system + FlexCath Contour™ steerable sheath
PulseSelect™ PFA catheter features
- 9 electrodes built to sense, ablate, and pace
- 25 mm diameter loop
- 9 Fr shaft with bidirectional steering
Fixed electrode spacing to produce a reliable field for predictable and consistent contiguous energy delivery
20-degree forward tilt to ensure more consistent uniform tissue contact
Trials
PULSED AF clinical trial1
PULSED AF evaluated the safety and effectiveness of the PulseSelect™ PFA system for the treatment of patients with paroxysmal and persistent atrial fibrillation and resulted in one of the lowest safety event rates of any AF ablation IDE trial to date.
0.7%
(primary safety event rate†)
70%
PAF
(freedom from AF/AFL/AT)
62%
PsAF
(freedom from AF/AFL/AT)
† Total of 13 adverse events measured; resulted in one cerebrovascular accident and one tamponade.
Ordering information
Resources
Related products
- Verma A, et al. Circulation. 2023;147:1422–1432.
- Yogarajah J, et al. J Clin Med. 2024;13:6961.
- Zylla MM, et al. Heart Rhythm. 2025;22:2201–2208.
- Katov L, et al. J Clin Med. 2024;13:7040.
- Molon G, et al. J Interv Card Electrophysiol. 2025;68:1475–1485.
- Abeln BGS, et al. J Cardiovasc Electrophysiol. 2025;36:1957–1965.
- Kawamura I, et al. Heart Rhythm. 2026;23:388–395.
- Gunawardene MA, et al. Int J Cardiol Heart Vasc. 2025;58:101674.
- Yogarajah J, et al. Heart Rhythm O2. 2025;6:1706–1715.
- Subin B, et al. J Cardiovasc Electrophysiol. 2025;36:2955–2962.
- Yamashita K, et al. Pacing Clin Electrophysiol. 2025;48:1196–1202.
- Masuda H, et al. Heart Rhythm. 2026;23:1517–1523.
- Shiomi S, et al. Heart Rhythm. 2026;23:25–31.
- Tscholl V, Chiba T, Formum P, et al. Pulse field ablation in patients with paroxysmal and persistent atrial fibrillation using the circular multielectrode array catheter: first outcome data in a real-world prospective study. J Interv Card Electrophysiol. Published online January 14, 2026.
- Beccarino N, et al. J Cardiovasc Electrophysiol. 2026;37:519–526.
- Goyal S, Bhimani A, Hoosien M. PVI Using the Pulse Select PFA System in Paroxysmal AF: One-Year Outcomes with Continuous Implantable Loop Recorder Monitoring. Poster presented at: AF Symposium 2026; February 5–7, 2026; Boston, MA.
- Verma A, Molon G, Lacotte J, et al. The REAL PULSE Global Registry: Real-world acute efficacy and safety outcomes for the use of a circular multielectrode array pulsed field ablation system for atrial fibrillation treatment. Poster presented at: HRS 2026; April 24–26, 2026; Chicago, IL.